Superworth

Neonc Technologies revenue NTHI

Sales by quarter and over the last twelve months, from 2024.

Last 12 months, to Dec 31, 2025
$40K
Latest quarter, Q4 FY25
$0
−100% on a year earlier
Fiscal year 2025
$40K
−52% on the year before

Neonc Technologies' revenue was $40K over the twelve months to Dec 31, 2025, down 52% on a year earlier.

In its latest quarter, Q4 FY25, it was $0, down 100% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$40K−52%
FY2024$83Kn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q4 FY25$0−100%$40K
Q3 FY25$0n/a$60K
Q2 FY25$0−100%$60K
Q1 FY25$40K−7%$80K
Q4 FY24$20Kn/a$83K
Q3 FY24$0n/an/a
Q2 FY24$20Kn/an/a
Q1 FY24$43Kn/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Neonc Technologies' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
NTHINeonc Technologiesn/m
LFVNLifevantage$182.6M−20% a year
SPROSpero Therapeutics$47M−3% a year
ATNMActinium Pharmaceuticalsn/m
NATRNatures Sunshine Products$492M+7% a year
ARVNArvinas$316.7M−15% a year
PBYIPuma Biotechnology$231.2M−3% a year
IRWDIronwood Pharmaceuticals$389.3M+26% a year
ZVRAZevra Therapeutics$136.1M+119% a year
CRMDCorMedix$462.2M+281% a year
COLLCollegium Pharmaceutical$808.2M+14% a year
Peer median$316.7M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Neonc Technologies

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.